Stem Cell Transplantation Clinical Trials at the Mario Lemieux Center for Blood Cancers

To learn more or speak with a trial coordinator, please call 412-864-6600.

15-060: A Phase 2 Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of Graft-Versus-Host Disease (GVHD)

This phase 2 trial studies how well selective T cell depletion works in preventing graft-versus-host disease (GVHD) in patients with acute lymphocytic leukemia, acute myeloid leukemia, or chronic myelogenous leukemia undergoing donor peripheral blood stem cell transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Removing a subset of the T cells from the donor cells before transplant may stop this from happening.

Principal Investigator: Warren Shlomchik, MD
Sponsor: Fred Hutchinson Cancer Research Center
Collaborators: National Cancer Institute, National Heart, Lung, and Blood Institute

View eligibility criteria and the full trial at ClinicalTrials.gov.

13-131: Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

The purpose of this study is to determine whether stem cells collected from a donor's blood stream will be as safe and effective as using bone marrow collected from a donor's pelvic bone.

Principal Investigator: Rafic Farah, MD

View eligibility criteria and the full trial at ClinicalTrials.gov.

17-004: Phase 3, Multicenter, Randomized, Double-Blind Study of Oral Ibrutinib in Combination with Corticosteroids Versus Placebo in Combination with Corticosteroids for New Onset Chronic Graft-Versus-Host Disease (GVHD)

To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects with newly diagnosed moderate to severe cGVHD.

Principal Investigator: Annie Im, MD
Sponsor: Pharmacyclics LLC

View eligibility criteria and the full trial at ClinicalTrials.gov.

17-081: Phase 3, Randomized, Double Blind Placebo Study of Itacitinib or Placebo in Combination with Steroids for TX of First-Line Acute Graft-Versus-Host Disease (GVHD)

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Principal Investigator: Annie Im, MD
Sponsor: Incyte Corporation

View eligibility criteria and the full trial at ClinicalTrials.gov.

17-097: A Pilot Study Evaluating the Efficacy of Non-Myeloablative Matched Related Donor Peripheral Blood Stem Cell Transplant in Patients with Severe Sickle Cell Disease

This is a prospective pilot study of matched-related donor allogeneic stem cell transplantation in adults with severe sickle cell disease using a matched-sibling PBSC graft with a non-myeloablative conditioning regimen (Alemtuzumab).

Principal Investigator: Kathleen Dorritie, MD

View eligibility criteria and the full trial listing at ClinicalTrials.gov.

17-100: Phase 3 Randomized, Open Label Study of Ruxolitinib Versus Best Available Therapy in Patients with Corticosteroid Refractory Chronic Graft-Versus-Host Disease (GVHD) After Allogenic Stem Cell Transplant

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Principal Investigator: Annie Im, MD
Sponsor: Incyte Corporation

View eligibility criteria and the full trial at ClinicalTrials.gov.

17-109: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.

Principal Investigator: Rafic Farah, MD

Cooperative Group: BMT CTN

View eligibility criteria and the full trial description at ClinicalTrials.gov.